| 出版应用/物种/样本/稀释 | 参考文献 |
|---|
| Kane M, Rebensburg S, Takata M, Zang T, Yamashita M, Kvaratskhelia M, et al. Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. elife. 2018;7: pubmed 出版商 |
| JoviÄić A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada S, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226-9 pubmed 出版商 |
| Konstantoulas C, Indik S. Mouse mammary tumor virus-based vector transduces non-dividing cells, enters the nucleus via a TNPO3-independent pathway and integrates in a less biased fashion than other retroviruses. Retrovirology. 2014;11:34 pubmed 出版商 |
| Henning M, Dubose B, Burse M, Aiken C, Yamashita M. In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog. 2014;10:e1003868 pubmed 出版商 |
| Fricke T, Valle Casuso J, White T, Brandariz Nuñez A, Bosche W, Reszka N, et al. The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6. Retrovirology. 2013;10:46 pubmed 出版商 |
| Swaminathan G, Rossi F, Sierra L, Gupta A, Navas Martin S, MARTIN GARCIA J. A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages. PLoS Pathog. 2012;8:e1002937 pubmed 出版商 |
| Price A, Fletcher A, Schaller T, Elliott T, Lee K, Kewalramani V, et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 2012;8:e1002896 pubmed 出版商 |
| Schaller T, Ocwieja K, Rasaiyaah J, Price A, Brady T, Roth S, et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 2011;7:e1002439 pubmed 出版商 |
| Ocwieja K, Brady T, Ronen K, Huegel A, Roth S, Schaller T, et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011;7:e1001313 pubmed 出版商 |
